soul trial oral semaglutide cardiovascular outcomes results 2024 nejm Long-term kidney of in obesity and disease in the SELECT Semaglutide, a glucagon-like peptide-1 (GLP-1)

I also found myself probably waking up less to pee in general than I normally would

The good news is that when used correctly under medical supervision , GH peptide therapies have an excellent safety record

Trulicity and Ozempic are not recommended for people with type 1 diabetes because they can increase the risk of low blood sugar and are mainly used for people with type 2 diabetes

bmiMD's sermorelin tablets as a finished compounded product have not been clinically studied for these outcomes

supplementation decisions should be individualised

It would therefore be interesting to determine if the opposite approach, i.e., simultaneously inhibiting ARC AgRP/NPY neurons and activating ARC POMC neurons, additively reduces food intake and leads to weight loss in the chronic setting as this would be therapeutically relevant